Laird Norton Wetherby Wealth Management LLC Sells 6,035 Shares of Novo Nordisk A/S (NYSE:NVO)

Laird Norton Wetherby Wealth Management LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 5.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 95,546 shares of the company’s stock after selling 6,035 shares during the period. Laird Norton Wetherby Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $8,219,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Diversified Trust Co raised its position in Novo Nordisk A/S by 13.9% during the 4th quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock valued at $279,000 after purchasing an additional 395 shares in the last quarter. ORG Partners LLC raised its position in Novo Nordisk A/S by 181.7% during the 4th quarter. ORG Partners LLC now owns 1,003 shares of the company’s stock valued at $86,000 after purchasing an additional 647 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Novo Nordisk A/S by 0.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company’s stock valued at $24,988,000 after purchasing an additional 1,051 shares in the last quarter. Fiduciary Alliance LLC raised its position in Novo Nordisk A/S by 11.4% during the 4th quarter. Fiduciary Alliance LLC now owns 8,107 shares of the company’s stock valued at $697,000 after purchasing an additional 829 shares in the last quarter. Finally, Capital Investment Advisors LLC raised its position in Novo Nordisk A/S by 12.1% during the 4th quarter. Capital Investment Advisors LLC now owns 4,435 shares of the company’s stock valued at $382,000 after purchasing an additional 478 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Up 1.4%

Shares of NVO stock opened at $65.75 on Monday. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The stock’s fifty day moving average price is $69.21 and its 200 day moving average price is $85.83. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market cap of $295.06 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $79.17 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on NVO shares. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating on the stock. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average price target of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.